baclofen has been researched along with Ambulation Disorders, Neurologic in 13 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the effect of continuous intrathecal baclofen infusion (ITB) on gait parameters of ambulant children with cerebral palsy (CP)." | 7.75 | Changes in gait following continuous intrathecal baclofen infusion in ambulant children and young adults with cerebral palsy. ( Brochard, S; Filipetti, P; Lempereur, M; Rémy-Néris, O, 2009) |
| "The mean daily dosage alleviating spasticity on the hemiparetic side-without affecting the nonparetic side-was 119 microg/day (range 50 to 360 microg/day)." | 6.74 | Limitations of intrathecal baclofen for spastic hemiparesis following stroke. ( Kofler, M; Quirbach, E; Saltuari, L; Schauer, R; Singer, M, 2009) |
| "To assess the effect of continuous intrathecal baclofen infusion (ITB) on gait parameters of ambulant children with cerebral palsy (CP)." | 3.75 | Changes in gait following continuous intrathecal baclofen infusion in ambulant children and young adults with cerebral palsy. ( Brochard, S; Filipetti, P; Lempereur, M; Rémy-Néris, O, 2009) |
| "The mean daily dosage alleviating spasticity on the hemiparetic side-without affecting the nonparetic side-was 119 microg/day (range 50 to 360 microg/day)." | 2.74 | Limitations of intrathecal baclofen for spastic hemiparesis following stroke. ( Kofler, M; Quirbach, E; Saltuari, L; Schauer, R; Singer, M, 2009) |
| "Walking performance and spasticity in lower-extremity muscles were assessed before and at 2, 4, and 6 hours after ITB bolus injection." | 2.71 | Effect of intrathecal baclofen bolus injection on temporospatial gait characteristics in patients with acquired brain injury. ( Horn, TS; Stokic, DS; Yablon, SA, 2005) |
| "Fourteen spastic MS patients were examined in a placebo controlled double-blind, cross-over trial of oral baclofen treatment." | 2.69 | Effect of baclofen on gait in spastic MS patients. ( Larsen, TK; Orsnes, GB; Ravnborg, M; Sørensen, PS, 2000) |
| "These patients suffered from spasticity due to many different diseases." | 1.38 | Intrathecal baclofen therapy for severe spasticity: analysis on a series of 112 consecutive patients and future prospectives. ( Mirone, G; Moraci, A; Natale, M; Rotondo, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Behm, K | 1 |
| Morgan, P | 1 |
| Arroyo González, R | 1 |
| Bolton, MM | 1 |
| Heaney, CF | 1 |
| Murtishaw, AS | 1 |
| Sabbagh, JJ | 1 |
| Magcalas, CM | 1 |
| Kinney, JW | 1 |
| Heetla, HW | 1 |
| Halbertsma, JP | 1 |
| Dekker, R | 1 |
| Staal, MJ | 1 |
| van Laar, T | 1 |
| Kofler, M | 1 |
| Quirbach, E | 1 |
| Schauer, R | 1 |
| Singer, M | 1 |
| Saltuari, L | 1 |
| Brochard, S | 1 |
| Lempereur, M | 1 |
| Filipetti, P | 1 |
| Rémy-Néris, O | 1 |
| Natale, M | 1 |
| Mirone, G | 1 |
| Rotondo, M | 1 |
| Moraci, A | 1 |
| Escaldi, SV | 1 |
| Cuccurullo, SJ | 1 |
| Terzella, M | 1 |
| Petagna, AM | 1 |
| Strax, TE | 1 |
| Molteni, F | 1 |
| Carda, S | 1 |
| Cazzaniga, M | 1 |
| Magoni, L | 1 |
| Rossini, M | 1 |
| Caimmi, M | 1 |
| Horn, TS | 1 |
| Yablon, SA | 1 |
| Stokic, DS | 1 |
| Kraemer, M | 1 |
| Berlit, P | 1 |
| Orsnes, GB | 1 |
| Sørensen, PS | 1 |
| Larsen, TK | 1 |
| Ravnborg, M | 1 |
| Patrick, JH | 1 |
| Roberts, AP | 1 |
| Cole, GF | 1 |
3 reviews available for baclofen and Ambulation Disorders, Neurologic
| Article | Year |
|---|---|
The effect of symptom-controlling medication on gait outcomes in people with multiple sclerosis: a systematic review.
Topics: 4-Aminopyridine; Baclofen; Cannabinoids; Gait Disorders, Neurologic; Humans; Multiple Sclerosis; Mus | 2018 |
A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.
Topics: Baclofen; Cannabidiol; Disease Progression; Dronabinol; Drug Combinations; Gait Disorders, Neurologi | 2018 |
Therapeutic choices in the locomotor management of the child with cerebral palsy--more luck than judgement?
Topics: Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Child; Gait Disorders, Neurologic; Humans; Injec | 2001 |
3 trials available for baclofen and Ambulation Disorders, Neurologic
| Article | Year |
|---|---|
Limitations of intrathecal baclofen for spastic hemiparesis following stroke.
Topics: Adolescent; Adult; Baclofen; Child; Dose-Response Relationship, Drug; Female; GABA Agonists; Gait Di | 2009 |
Effect of intrathecal baclofen bolus injection on temporospatial gait characteristics in patients with acquired brain injury.
Topics: Adult; Baclofen; Brain Injuries; Computers; Female; Gait Disorders, Neurologic; Humans; Injections, | 2005 |
Effect of baclofen on gait in spastic MS patients.
Topics: Adult; Analysis of Variance; Baclofen; Cross-Over Studies; Dose-Response Relationship, Drug; Double- | 2000 |
7 other studies available for baclofen and Ambulation Disorders, Neurologic
| Article | Year |
|---|---|
Postnatal alterations in GABAB receptor tone produce sensorimotor gating deficits and protein level differences in adulthood.
Topics: Acoustic Stimulation; Age Factors; Animals; Animals, Newborn; Baclofen; Body Weight; Brain; Disease | 2015 |
Improved gait performance in a patient with hereditary spastic paraplegia after a continuous intrathecal baclofen test infusion and subsequent pump implantation: a case report.
Topics: Baclofen; Electromyography; GABA-B Receptor Agonists; Gait Disorders, Neurologic; Humans; Infusion P | 2015 |
Changes in gait following continuous intrathecal baclofen infusion in ambulant children and young adults with cerebral palsy.
Topics: Adolescent; Baclofen; Biomechanical Phenomena; Cerebral Palsy; Child; Female; Gait Disorders, Neurol | 2009 |
Intrathecal baclofen therapy for severe spasticity: analysis on a series of 112 consecutive patients and future prospectives.
Topics: Adolescent; Adult; Baclofen; Child; Consciousness Disorders; Disabled Persons; Dose-Response Relatio | 2012 |
Assessing competency in spasticity management: a method of development and assessment.
Topics: Baclofen; Botulinum Toxins; Clinical Competence; Curriculum; Documentation; Educational Measurement; | 2012 |
Instrumental evaluation of gait modifications before and during intrathecal baclofen therapy: a 2-year follow-up case study.
Topics: Adult; Baclofen; Follow-Up Studies; Gait Disorders, Neurologic; Humans; Injections, Spinal; Male; Mu | 2005 |
Progressive encephalomyelitis with rigidity and myoclonus in an 81-year-old patient.
Topics: Aged, 80 and over; Anti-Inflammatory Agents; Baclofen; Electromyography; Encephalomyelitis; Female; | 2008 |